FY2024 · ended Dec 31, 2024 · Revenue $0, -100.0% YoY · Filed Mar 26, 2026
Inhibikase Therapeutics, Inc. (IKT) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$27.8 million.
Revenue
$0
-100.0% vs prior year
Net income (TTM)
$-60.64M
-46.1% vs year-ago TTM
Operating cash flow (TTM)
$-42.61M
-114.1% vs year-ago TTM
Free cash flow (TTM)
$-42.61M
-113.9% vs year-ago TTM
EPS (TTM)
$-0.43
+32.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
132.03M
+77.6% vs prior year
Net cash
$138.44M
FY 2024
Operating margin
-7712.0%
FY 2023
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- IKT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Wilmington, DE
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1750149
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | $0 | $260,501 | $123,440 | $3.1M |
| Operating income | -$52.0M | -$28.6M | -$20.1M | -$18.1M | -$14.8M |
| Net income | -$48.3M | -$27.5M | -$19.0M | -$18.1M | -$14.8M |
| Diluted EPS | -$0.49 | -$1.16 | -$3.16 | -$4.28 | — |
| Operating cash flow | -$27.8M | -$19.1M | -$18.1M | -$17.4M | -$14.3M |
| Free cash flow | -$27.8M | -$19.1M | -$18.1M | -$17.6M | — |
| Total assets | $181.2M | $98.6M | $14.5M | $24.9M | $42.5M |
| Total liabilities | $8.3M | $3.7M | $3.5M | $3.9M | $4.1M |
| Stockholders' equity | $172.9M | $94.9M | $11.0M | $21.0M | $38.4M |
| Cash and investments | $218.3M | $138.6M | $13.3M | $23.1M | $40.8M |
| Total debt | — | $110,517 | $622,003 | $351,288 | $248,911 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 20, 2026 | Oct 19, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 8, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Auditor change
|
Aug 26, 2026 | Aug 21, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Unregistered share sale
|
Jul 29, 2026 | Jul 29, 2026 |
All 368 Inhibikase Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.